Results 271 to 280 of about 774,999 (361)
Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.
Abdelaziz A +3 more
europepmc +1 more source
The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings. [PDF]
Beinfeld MT +5 more
europepmc +1 more source
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee +3 more
wiley +1 more source
Impact of clinical factors and season on inflammatory cytokines in biologic-treated and untreated asthma. [PDF]
Nopsopon T +10 more
europepmc +1 more source
Thrombolytic proteins profiling: High‐throughput activity, selectivity, and resistance assays
We present optimized biochemical protocols for evaluating thrombolytic proteins, enabling rapid and robust screening of enzymatic activity, inhibition resistance, and fibrin affinity, stimulation, and selectivity. The outcome translates to key clinical indicators such as biological half‐life and bleeding risk. These assays streamline the development of
Martin Toul +3 more
wiley +1 more source
Global prevalence of eligibility for biologic therapy in ATS/ERS-defined severe asthma: A systematic review. [PDF]
Yang F +4 more
europepmc +1 more source
Calcium and phosphate and their role in matrix vesicles: A biological view
Larwsk Hayann +3 more
openalex +1 more source
Overview of molecular signatures of senescence and associated resources: pros and cons
Cells can enter a stress response state termed cellular senescence that is involved in various diseases and aging. Detecting these cells is challenging due to the lack of universal biomarkers. This review presents the current state of senescence identification, from biomarkers to molecular signatures, compares tools and approaches, and highlights ...
Orestis A. Ntintas +6 more
wiley +1 more source

